Your browser doesn't support javascript.
loading
Impact of treatment experience on patient knowledge of colony-stimulating factors among patients receiving cancer chemotherapy: evidence from S1415CD-a large pragmatic trial.
Lyman, Gary H; Bansal, Aasthaa; Sullivan, Sean D; Arnold, Kathryn B; Barlow, William E; Hershman, Dawn L; Lad, Thomas E; Ramsey, Scott D.
Afiliación
  • Lyman GH; Fred Hutchinson Cancer Center, 1100 Fairview Ave N. Mailstop M3-B232, Seattle, WA, 98109, USA.
  • Bansal A; School of Medicine, University of Washington, Seattle, WA, USA.
  • Sullivan SD; Fred Hutchinson Cancer Center, 1100 Fairview Ave N. Mailstop M3-B232, Seattle, WA, 98109, USA.
  • Arnold KB; School of Pharmacy, University of Washington, Seattle, WA, USA.
  • Barlow WE; School of Pharmacy, University of Washington, Seattle, WA, USA.
  • Hershman DL; Fred Hutchinson Cancer Center, 1100 Fairview Ave N. Mailstop M3-B232, Seattle, WA, 98109, USA.
  • Lad TE; SWOG Statistics and Data Management Center, Seattle, WA, USA.
  • Ramsey SD; Fred Hutchinson Cancer Center, 1100 Fairview Ave N. Mailstop M3-B232, Seattle, WA, 98109, USA.
Support Care Cancer ; 31(10): 598, 2023 Sep 28.
Article en En | MEDLINE | ID: mdl-37770704
PURPOSE: Primary prophylactic granulocyte colony-stimulating factors (PP-CSFs) are prescribed alongside chemotherapy regimens that carry a significant risk of febrile neutropenia (FN). As part of S1415CD, a prospective, pragmatic trial evaluating the impact of automated orders to improve PP-CSF prescribing, we evaluated patients' baseline knowledge of PP-CSF and whether that knowledge improved following the first cycle of chemotherapy. METHODS: Adult patients with breast, colorectal, or non-small-cell lung cancer initiating chemotherapy were enrolled in S1415CD between January 2016 and April 2020. Eight questions assessing knowledge of CSF indications, risks, benefits, and out-of-pocket costs were included in a baseline survey and in a follow-up survey at the end of the first cycle of chemotherapy. Responses were stratified by the trial arm and whether chemotherapy was low, intermediate, or high FN risk. RESULTS: Of the 3605 eligible patients, 3580 (99.3%) completed the baseline survey, and 3420 (95.5%) completed the follow-up survey. At baseline, 803 (22.4%) patients responded "Don't know" to all 8 questions, and all patients averaged 2.75 correct questions. At follow-up, knowledge increased by 0.34 in the high-FN-risk group (p < 0.001) but declined for the other FN-risk groups. In multivariate analysis, receiving a high-FN-risk regimen and younger age were significantly associated with knowledge improvement. CONCLUSION: Chemotherapy patients had poor knowledge of PP-CSF that improved only modestly among recipients of high-FN-risk chemotherapy. Further efforts to inform patients about the risks, benefits, and costs of PP-CSF may be warranted, particularly for those in whom prophylaxis is indicated. TRIAL REGISTRATION: NCT02728596, April 6, 2016.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma de Pulmón de Células no Pequeñas / Neutropenia Febril / Neoplasias Pulmonares Límite: Adult / Female / Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma de Pulmón de Células no Pequeñas / Neutropenia Febril / Neoplasias Pulmonares Límite: Adult / Female / Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania